Allarity Therapeutics (NASDAQ:ALLR) Given New $10.25 Price Target at Ascendiant Capital Markets

Allarity Therapeutics (NASDAQ:ALLR) had its target price hoisted by investment analysts at Ascendiant Capital Markets from $9.75 to $10.25 in a report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Several other research analysts have also issued reports on ALLR. Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Monday, April 20th. Wall Street Zen upgraded Allarity Therapeutics to a “hold” rating in a research report on Saturday, May 30th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $10.25.

Allarity Therapeutics Stock Performance

Shares of ALLR opened at $1.61 on Monday. The firm has a market capitalization of $25.62 million, a price-to-earnings ratio of -2.24 and a beta of 0.52. The business’s fifty day moving average price is $1.40 and its two-hundred day moving average price is $1.20. Allarity Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.35.

Allarity Therapeutics (NASDAQ:ALLR) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.05. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. As a group, research analysts forecast that Allarity Therapeutics will post -0.96 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its stake in Allarity Therapeutics by 274.1% during the 4th quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after buying an additional 181,426 shares during the period. Citadel Advisors LLC acquired a new stake in Allarity Therapeutics during the 3rd quarter worth $149,000. Private Advisor Group LLC acquired a new stake in Allarity Therapeutics during the 3rd quarter worth $441,000. XTX Topco Ltd acquired a new stake in Allarity Therapeutics during the 4th quarter worth $36,000. Finally, DRW Securities LLC acquired a new stake in Allarity Therapeutics during the 4th quarter worth $133,000. 11.53% of the stock is currently owned by institutional investors.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical?stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small?molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid?stage clinical trials.